Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (16) Data Exclusivities (4) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (15) Right to Health (1) TAMU (1) Trade Policy (1) TRIPS (16) TRIPS Flexibilities (2) Vaccines (3) Voluntary Licenses (1) Archives Archives Select Month July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (12) Srividhya Ragavan (8) Shirin Syed (2) Micheal Palmedo (1) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS India’s Vaccination Policy and the Covid-19 Second Wave: Lessons for the World An Open letter to the United States Trade Representative on the TRIPS Waiver Re-Calibrating COVID Diplomacy 2021: A Changed IP Landscape for Defeating COVID-19 The Under-Appreciated Virtue of Transparency in Combatting COVID-19
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
